TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic based exercise.
Description: exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land-based exercise.
Description: land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land-based exercise.
Description: land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
Study: NCT03384459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the 308-nm excimer laser
Description: For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
Study: NCT03184883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single conventional denture
Description: mandibular conventional denture with soft liner

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single flexible denture
Description: mandibular flexible compete denture
Study: NCT03504891

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI prior to CRT Upgrade
Description: We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI prior to de novo CRT
Description: We will perform MRI prior to de novo CRT implants as the comparison group.
Study: NCT02822742

Intervention type: DRUG
Group type: OTHER
Intervention: DE-117 ophthalmic solution
Study: NCT06445465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1216
Description: \[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
Study: NCT03986242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rolling
Description: use non- vibration rolling and the total time is 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration rolling
Description: use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching
Description: static stretching and the total time is 20 minutes.
Study: NCT02822742

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost ophthalmic solution 0.005%
Study: NCT03283488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol
Description: Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
Study: NCT02146053

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulfate
Description: ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
Study: NCT02208596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study: NCT04966039

Intervention type: OTHER
Intervention: No intervention.
Description: There was no intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: There was no intervention.
Study: NCT02146053

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules: methyl cellulose
Study: NCT01253369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT02287857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domestic Tenofovir Disoproxil Fumarate Tablets
Description: 1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate Tablets of Gilead
Description: 1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
Study: NCT04635150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Close Collaboration with Parents
Description: Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
Study: NCT01658605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1605786
Description: 500 mg twice daily administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mg twice daily administered orally
Study: NCT01569737

Intervention type: DRUG
Intervention: ella
Description: ella, single intake, tablet 30mg
Study: NCT03232827

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flavored-Sweetened Waterpipe Tobacco
Description: Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unflavored-sweetened waterpipe tobacco
Description: Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unflavored-very low sweetened waterpipe tobacco
Description: Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flavored-very low sweetened waterpipe
Description: Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
Study: NCT03522415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate（MTX）
Description: Methotrexate is a slow-acting antirheumatic drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate（MTX）
Description: Methotrexate is a slow-acting antirheumatic drug.
Study: NCT00773643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
Study: NCT03114111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid (ALA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01648023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gem-Cis or Gem-Carbo
Study: NCT01876680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and aerobic exercise
Description: Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year.
Study: NCT01896778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia Treatment
Description: Undergo B-WARM
Study: NCT01989819

Intervention type: OTHER
Intervention: skin biopsy
Study: NCT01896778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia Treatment
Description: Undergo B-WARM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01236261

Intervention type: OTHER
Intervention: Non intervention
Description: Non interventional study
Study: NCT04620616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
Study: NCT03984838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
Description: JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
Study: NCT00708903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT01436695

Intervention type: DEVICE
Intervention: Epicall
Description: The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
Study: NCT01595438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime - Avibactam ( CAZ-AVI)
Description: Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study: NCT05191732

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma; Bone marrow concentrate
Description: Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma; Bone marrow concentrate
Description: Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
Study: NCT01000025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-00299804
Description: PF-804 45 mg PO, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 45 mg PO, daily
Study: NCT01716026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevazizumab intravitreal injection
Description: Intravitreal injection of bevacizumab
Study: NCT04508010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR
Description: Participants will receive an IVR survey
Study: NCT01716026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevazizumab intravitreal injection
Description: Intravitreal injection of bevacizumab
Study: NCT03001323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec
Description: Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard long-acting
Description: Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Study: NCT04620616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Usual Brand ENDS
Description: Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
Study: NCT02452710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Open-label placebo
Study: NCT02829008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose-bevacizumab/pemetrexed
Description: Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
Study: NCT00651313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal gel administered once daily for 4 days
Study: NCT00143988

Intervention type: BEHAVIORAL
Intervention: Treadmill testing
Description: Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded

Intervention type: BEHAVIORAL
Intervention: Treadmill testing
Description: Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded

Intervention type: BEHAVIORAL
Intervention: Ambulatory Blood Pressure and Heart Rate Monitoring
Description: Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.

Intervention type: BEHAVIORAL
Intervention: Ambulatory Blood Pressure and Heart Rate Monitoring
Description: Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
Study: NCT01612442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and agricultural education
Description: Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
Study: NCT04508010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATI
Description: Participants will receive a CATI survey
Study: NCT00005808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo laser therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop electrosurgical excision procedure
Description: Undergo LEEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop electrosurgical excision procedure
Description: Undergo LEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00101153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study: NCT03393689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2